Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cadonilimab vs sintilimab plus perioperative SOX in diffuse locally advanced gastric/GEJ adenocarcinoma
ChiCTR2500106399Phase 3Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Cadonilimab + SOX with Sintilimab + SOX (2 arms). Primary endpoints: Pathological complete response rate and Median disease-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cadonilimabsintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500106399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106399.